Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
Status:
Unknown status
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The prognosis of patients with inoperable locally advanced or residual/relapsed gastric
cancer is rather poor. Concurrent capecitabine chemoradiotherapy is safe and recommended.
Nimotuzumab, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody, has shown
its antitumor safety and efficiency in many phase I/II studies. Efficiency of combination of
these treatment need to be further analyzed.